Aubagio
Novartis announce robust Phase 3 trials for ofatumumab in MS
September 16, 2019Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis
Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …
NICE final ‘yes’ for Biogen’s MS pill
August 27, 2014Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya
In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …
Analysts ‘disappointed’ by Sanofi guidance
February 6, 2014Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales
Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
NICE recommends Aubagio
January 22, 2014Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya
NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
NICE: we need more Aubagio data
September 18, 2013Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi
Sanofi’s Lemtrada given European go ahead
September 18, 2013Research and Development, Sales and Marketing Aubagio, Lemtrada, MS, Sanofi, gilenya
Aubagio approved in Europe
September 3, 2013Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera
Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …
Genzyme MS drug approved in US
September 13, 2012Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis
US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …
Latest content
FibroFind appoints Lee Borthwick as CEO
